Stem Cell Therapy and Congenital Heart Disease
AbstractFor more than a decade, stem cell therapy has been the focus of intensive efforts for the treatment of adult heart disease, and now has promise for treating the pediatric population. On the basis of encouraging results in the adult field, the application of stem cell-based strategies in children with congenital heart disease (CHD) opens a new therapy paradigm. To date, the safety and efficacy of stem cell-based products to promote cardiac repair and recovery in dilated cardiomyopathy and structural heart disease in infants have been primarily demonstrated in scattered clinical case reports, and supported by a few relevant pre-clinical models. Recently the TICAP trial has shown the safety and feasibility of intracoronary infusion of autologous cardiosphere-derived cells in children with hypoplastic left heart syndrome. A focus on preemptive cardiac regeneration in the pediatric setting may offer new insights as to the timing of surgery, location of cell-based delivery, and type of cell-based regeneration that could further inform acquired cardiac disease applications. Here, we review the current knowledge on the field of stem cell therapy and tissue engineering in children with CHD, and discuss the gaps and future perspectives on cell-based strategies to treat patients with CHD. View Full-Text
Share & Cite This Article
Nelson, T.J.; Cantero Peral, S. Stem Cell Therapy and Congenital Heart Disease. J. Cardiovasc. Dev. Dis. 2016, 3, 24.
Nelson TJ, Cantero Peral S. Stem Cell Therapy and Congenital Heart Disease. Journal of Cardiovascular Development and Disease. 2016; 3(3):24.Chicago/Turabian Style
Nelson, Timothy J.; Cantero Peral, Susana. 2016. "Stem Cell Therapy and Congenital Heart Disease." J. Cardiovasc. Dev. Dis. 3, no. 3: 24.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.